Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.64) by 3.13 percent. This is a 78 percent increase over losses of $(3.00) per share from the same period last year.
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition In Small Cell Lung Cancer Murine Model
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib
Results support designating small cell lung cancer as first
